View Item 

Show simple item record

Pharmacologic Properties of Proton Pump Inhibitors
dc.contributor.authorWelage, Lynda S.en_US
dc.date.accessioned2012-03-16T15:57:20Z
dc.date.available2012-03-16T15:57:20Z
dc.date.issued2003-10en_US
dc.identifier.citationWelage, Lynda S. (2003). "Pharmacologic Properties of Proton Pump Inhibitors." Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 23(10P2): 74S-80S. <http://hdl.handle.net/2027.42/90231>en_US
dc.identifier.issn0277-0008en_US
dc.identifier.issn1875-9114en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/90231
dc.publisherWiley Periodicals, Inc.en_US
dc.publisherBlackwell Publishing Ltden_US
dc.titlePharmacologic Properties of Proton Pump Inhibitorsen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Clinical Sciences, University of Michigan College of Pharmacy, Ann Arbor, Michigan.en_US
dc.identifier.pmid14587961en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/90231/1/phco.23.13.74S.31929.pdf
dc.identifier.doi10.1592/phco.23.13.74S.31929en_US
dc.identifier.sourcePharmacotherapy: The Journal of Human Pharmacology and Drug Therapyen_US
dc.identifier.citedreferenceKhoury RM, Katz PO, Castell DO Post‐prandial ranitidine is superior to post‐prandial omeprazole in control of gastric acidity in healthy volunteers. Aliment Pharmacol Ther 1999; 13: 1211 – 14.en_US
dc.identifier.citedreferenceFuruta T., Ohashi K., Kamata T., et al. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med 1998; 129: 1027 – 30.en_US
dc.identifier.citedreferenceWolfe MM, Sachs G. Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress‐related erosive syndrome. Gastroenterology 2000; 118: S9 – 31.en_US
dc.identifier.citedreferencePrichard PJ, Yeomans ND, Mihaly GW, et al. Omeprazole: a study of its inhibition of gastric pH and oral pharmacokinetics after morning or evening dosage. Gastroenterology 1985; 88: 64 – 9.en_US
dc.identifier.citedreferenceTAP Pharmaceuticals. Prevacid (lansoprazole) package insert. Lake Forest, IL; 2002.en_US
dc.identifier.citedreferenceWyeth Laboratories. Protonix (pantoprazole) delayed‐release tablets package insert. Philadelphia, PA; 2001.en_US
dc.identifier.citedreferenceAstraZeneca. Prilosec (omeprazole) package insert. Wilmington, DE; 2000.en_US
dc.identifier.citedreferenceJunghard O., Hassan‐Alin M., Hasselgren G. The effect of the area under the plasma concentration vs time curve and the maximum plasma concentration of esomeprazole on intragastric pH. Eur J Clin Pharmacol 2002; 58: 453 – 8.en_US
dc.identifier.citedreferenceMerki HS, Wilder‐Smith CH Do continuous infusions of omeprazole and ranitidine retain their effect with prolonged dosing? Gastroenterology 1994; 106: 60 – 4.en_US
dc.identifier.citedreferenceGillen D., McColl KE Problems related to acid rebound and tachyphylaxis. Baillieres Best Pract Res Clin Gastroenterol 2001; 15: 487 – 95.en_US
dc.identifier.citedreferenceHuang JQ, Hunt RH Pharmacological and pharmacodynamic essentials of H(2)‐receptor antagonists and proton pump inhibitors for the practising physician. Baillieres Best Pract Res Clin Gastroenterol 2001; 15: 355 – 70.en_US
dc.identifier.citedreferenceWaldum HL, Arnestad JS, Brenna E., Eide I., Syversen U., Sandvik AK Marked increase in gastric acid secretory capacity after omeprazole treatment. Gut 1996; 39: 649 – 53.en_US
dc.identifier.citedreferenceLarsson H., Carlsson E., Ryberg B., Fryklund J., Wallmark B. Rat parietal cell function after prolonged inhibition of gastric acid secretion. Am J Physiol 1988; 254: G33 – 9.en_US
dc.identifier.citedreferenceWelage LS, Berardi RR Drug interactions with antiulcer agents: considerations in the treatment of acid‐peptic disease. J Pharm Pract 1994; 6: 177 – 95.en_US
dc.identifier.citedreferenceAndersson T., Hassan‐Alin M., Hasselgren G., Rohss K. Drug interaction studies with esomeprazole, the (S)‐isomer of omeprazole. Clin Pharmacokinet 2001; 40: 523 – 37.en_US
dc.identifier.citedreferenceWelage LS, Berardi RR Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid‐related diseases. J Am Pharm Assoc (Wash) 2000; 40: 52 – 62.en_US
dc.identifier.citedreferenceAnonymous.. Pantoprazole IV (Protonix IV). Med Lett Drugs Ther 2002; 44: 41 – 2.en_US
dc.identifier.citedreferenceWyeth Laboratories. Protonix IV (pantoprazole IV) package insert. Philadelphia, PA; 2002.en_US
dc.identifier.citedreferencePisegna JR Switching between intravenous and oral pantoprazole. J Clin Gastroenterol 2001; 32: 27 – 32.en_US
dc.identifier.citedreferenceMetz DC Potential uses of intravenous proton pump inhibitors to control gastric acid secretion. Digestion 2000; 62: 73 – 81.en_US
dc.identifier.citedreferenceFeldman M.. Gastric secretion: normal and abnormal. In: Feldman M., Scharschmidt BF, Sleisenger MH, eds. Gastrointestinal and liver disease. Philadelphia: WB Saunders, 1998: 587 – 603.en_US
dc.identifier.citedreferenceModlin IM, Sachs G., eds. Gastric acid secretion. In: Acid related diseases: biology and treatment. Konstanz, Germany: Schnetztor‐Verlag GmbH D‐Konstanz, 1998: 61 – 91.en_US
dc.identifier.citedreferenceOlbe L., ed. Proton pump inhibitors. Basel: Birkhauser Verlag, 1999.en_US
dc.identifier.citedreferenceMetz DC, Ferron GM, Paul J., et al. Proton pump activation in stimulated parietal cells is regulated by gastric acid secretory capacity: a human study. J Clin Pharmacol 2002; 42: 512 – 19.en_US
dc.identifier.citedreferenceHasselgren G., Hassan‐Alin M., Andersson T., Claar‐Nilsson C., Rohss K. Pharmacokinetic study of esomeprazole in the elderly. Clin Pharmacokinet 2001; 40: 145 – 50.en_US
dc.identifier.citedreferenceAstraZeneca. Nexium (esomeprazole) package insert. Wilmington, DE; 2000.en_US
dc.identifier.citedreferenceKromer W.. Relative efficacies of gastric proton‐pump inhibitors on a milligram basis: desired and undesired SH reactions. Impact of chirality. Scand J Gastroenterol 2001; 36 ( suppl 234 ): 3 – 9.en_US
dc.identifier.citedreferencePetersen KU. Comparison of different proton pump inhibitors. In: Olbe L., ed. Proton pump inhibitors. Basel: Birkhauser Verlag, 1999: 143 – 57.en_US
dc.identifier.citedreferenceKromer W. Similarities and differences in the properties of substituted benzimidazoles: a comparison between panto‐prazole and related compounds. Digestion 1995; 56: 443 – 54.en_US
dc.identifier.citedreferenceAndersson T., Holmberg J., Rohss K., Walan A. Pharmaco‐kinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole. Br J Clin Pharmacol 1998; 45: 369 – 75.en_US
dc.identifier.citedreferenceWelage LS, Karlstadt RG, Burton MS, Lynn RB Pharmaco‐kinetic comparison of five proton pump inhibitors. Presented at Digestive Disease Week, San Francisco, May 1922, 2002.en_US
dc.identifier.citedreferenceSpencer CM, Fauds D. Esomeprazole. Drugs 2000; 60: 321 – 9.en_US
dc.identifier.citedreferenceBenet LZ, Zech K. Pharmacokinetics—a relevant factor for the choice of a drug? Aliment Pharmacol Ther 1994; 8 ( suppl 1 ): 25 – 32.en_US
dc.identifier.citedreferenceKromer W., Kruger U., Huber R., Hartmann M., Steinijans VW Differences in pH‐dependent activation rates of substituted benzimidazoles and biological in vitro correlates. Pharmacology 1998; 56: 57 – 70.en_US
dc.identifier.citedreferenceBesancon M., Simon A., Sachs G., Shin JM Sites of reaction of the gastric H,K‐ATPase with extracytoplasmic thiol reagents. J Biol Chem 1997; 272: 22438 – 46.en_US
dc.identifier.citedreferenceShin JM, Sachs G. Restoration of acid secretion following treatment with proton pump inhibitors. Gastroenterology 2002; 123: 1588 – 97.en_US
dc.identifier.citedreferenceGedda K., Scott D., Besancon M., Lorentzon P., Sachs G. Turnover of the gastric H+,K+‐adenosine triphosphatase a subunit and its effect on inhibition of rat gastric acid secretion. Gastroenterology 1995; 109: 1134 – 41.en_US
dc.identifier.citedreferenceKatashima M., Yamamoto K., Tokuma Y., et al. Comparative pharmacokinetic/pharmacodynamic analysis of proton pump inhibitors omeprazole, lansoprazole and pantoprazole, in humans. Eur J Drug Metab Pharmacokinet 1998; 23: 19 – 26.en_US
dc.identifier.citedreferencePue MA, Laroche J., Meineke I., de Mey C. Pharmacokinetics of pantoprazole following single intravenous and oral administration to healthy male subjects. Eur J Clin Pharmacol 1993; 44: 575 – 8.en_US
dc.identifier.citedreferenceAndersson T., Hassan‐Alin M., Hasselgren G., Rohss K., Weidolf L. Pharmacokinetic studies with esomeprazole, the (S)‐isomer of omeprazole. Clin Pharmacokinet 2001; 40: 411 – 26.en_US
dc.identifier.citedreferenceAndersson T., Andren K., Cederberg C., Lagerstrom PO, Lundborg P., Skanberg I. Pharmacokinetics and bioavailability of omeprazole after single and repeated oral administration in healthy subjects. Br J Clin Pharmacol 1990; 29: 557 – 63.en_US
dc.identifier.citedreferenceChing MS, Mihaly GW, Angus PW, et al. Oral bioavailability of omeprazole before and after chronic therapy in patients with duodenal ulcer. Br J Clin Pharmacol 1991; 31: 166 – 70.en_US
dc.identifier.citedreferenceHassan‐Alin M., Andersson T., Bredberg E., Rohss K. Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. Eur J Clin Pharmacol 2000; 56: 665 – 70.en_US
dc.identifier.citedreferenceSimon B., Muller P., Marinis E., et al. Effect of repeated oral administration of BY 1023/SK&F 96022—a new substituted benzimidazole derivative—on pentagastrin‐stimulated gastric acid secretion and pharmacokinetics in man. Aliment Pharmacol Ther 1990; 4: 373 – 9.en_US
dc.identifier.citedreferenceLandes BD, Petite JP, Flouvat B. Clinical pharmacokinetics of lansoprazole. Clin Pharmacokinet 1995; 28: 458 – 70.en_US
dc.identifier.citedreferenceYasuda S., Ohnishi A., Ogawa T., et al. Pharmacokinetic properties of E3810, a new proton pump inhibitor, in healthy male volunteers. Int J Clin Pharmacol Ther 1994; 32: 466 – 73.en_US
dc.identifier.citedreferenceStedman CA, Barclay ML Comparison of the pharmaco‐kinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther 2000; 14: 963 – 78.en_US
dc.identifier.citedreferenceEisai Co. Aciphex (rabeprazole sodium) delayed‐release tablets. Teaneck, NJ; 2001.en_US
dc.identifier.citedreferenceIshizaki T., Chiba K., Manabe K., et al. Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S‐mephenytoin 4'‐hydroxylation. Clin Pharmacol Ther 1995; 58: 155 – 64.en_US
dc.identifier.citedreferenceSakai T., Aoyama N., Kita T., et al. CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects. Pharm Res 2001; 18: 721 – 7.en_US
dc.identifier.citedreferenceFuruta T., Ohashi K., Kosuge K., et al. CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin Pharmacol Ther 1999; 65: 552 – 61.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
phco.23.13.74S.31929.pdf
Size:
144.1KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.